Previous Close | 2.0700 |
Open | 2.0900 |
Bid | 2.0400 x 0 |
Ask | 2.0400 x 0 |
Day's Range | 2.0200 - 2.1200 |
52 Week Range | 1.4800 - 4.4900 |
Volume | |
Avg. Volume | 93,322 |
Market Cap | 149.734M |
Beta (5Y Monthly) | 1.74 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.5100 |
Earnings Date | Nov 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.71 |
Subscribe to Yahoo Finance Plus to view Fair Value for ONC.TO
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab...
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC).
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2023 Earnings Call Transcript November 3, 2023 Oncolytics Biotech Inc. misses on earnings expectations. Reported EPS is $-0.1 EPS, expectations were $-0.07. Operator: Good morning, and welcome to Oncolytics Biotech’s Third Quarter 2023 Conference Call. All participants are now in listen-only mode. There will be a question-and-answer session at the […]